• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novotech in Joint Venture with Indian CRO, Focuses on Asian Expansion

Novotech in Joint Venture with Indian CRO, Focuses on Asian Expansion

May 18, 2009
CenterWatch Staff

In keeping with its strategic focus on expanding in Asia, Australia-based contract research organization (CRO) Novotech has entered into a joint venture with ETI Klinical, a CRO based in Bangalore, India, and part of the Karle Group.

Novotech already had, and will keep, its own office in Hyderabad, India. Together the two Indian offices have 25 employees. Novotech has 90 employees in its Australia office and five each in its New Zealand and South Korea offices.

“The joint venture essentially gives us full-scale operations in India, including regulatory, biometrics, clinical, etc.,” said Alek Safarian, president and CEO of Novotech, at IIR’s Partnerships with CROs conference in Orlando. “We treat our operations and those of ETI Klinical as one entity.”

According to a statement by Karle Group CEO Mahendra Karle, ETI offers clients of the joint venture 92 pre-qualified sites across India with access to five million patients and 13,000 beds.

Novotech is growing its existing presence in Asia and expanding into other Asian countries. The focus on expanding only in Asia- Pacific countries represents a shift in strategy for Novotech. A year ago, the company’s plans included looking at possibly acquiring a similarly sized CRO in the U.S. by the end of summer 2008. Its expansion plans have changed as the U.S. economy worsened.

“Our plans have shifted a bit during the last year in that our focus is now fully on going into Asia,” Safarian said. “We’re deemphasizing our operations growth into the U.S. That’s, in part, brought about by the whole financial crisis…there has been a very noticeably stronger shift toward Asia- Pacific for our business during the height of the financial crisis.”

Novotech is doing feasibility studies for further Asian expansion.

“Our plan is by the end of 2009 to open in one or possibly two new countries. We are looking at seven right now. My guess would be that at about mid-year, we will have taken our first steps toward that,” Safarian said.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing